Jay Mehta Selected Research

Therapeutics

1/2019	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.
10/2018	Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
1/2018	High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.
1/2018	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease.
4/2012	Laboratory testing in pediatric rheumatology.
1/2009	Peritoneal tuberculosis: modern peril for an ancient disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jay Mehta Research Topics

Disease

6	Neoplasms (Cancer) 11/2023 - 07/2010
5	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 12/2019 - 01/2018
2	Lupus Nephritis 10/2018 - 08/2010
1	Pseudarthrosis (Pseudoarthrosis) 09/2023
1	Deglutition Disorders (Dysphagia) 09/2023
1	Intervertebral Disc Degeneration 07/2023
1	Spondylolisthesis 07/2023
1	Endometrial Neoplasms (Endometrial Cancer) 08/2021
1	COVID-19 11/2020
1	Sarcoma (Soft Tissue Sarcoma) 01/2016
1	Castleman Disease (Castleman's Disease) 01/2016
1	Myopericytoma 01/2016
1	Leukemia 01/2015
1	Fistula 04/2013
1	Rheumatic Diseases (Rheumatism) 04/2012
1	Infections 08/2009
1	Tuberculous Peritonitis 01/2009
1	Tuberculosis (Tuberculoses) 01/2009

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2009
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 01/2018
1	Immune Checkpoint InhibitorsIBA 11/2023
1	Dichlorodiphenyldichloroethane (DDD)IBA 07/2023
1	ParaffinIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Adenosine (Adenocard)FDA LinkGeneric 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Formaldehyde (Formol)FDA Link 01/2022
1	PlatinumIBA 08/2021
1	ChromatinIBA 08/2021
1	Sucrose (Saccharose)IBA 08/2021
1	Oxygen (Dioxygen)IBA 11/2020
1	Antirheumatic Agents (DMARD)IBA 12/2019
1	S100A12 ProteinIBA 01/2019
1	chlorotriphenylsilane (CTPS)IBA 10/2018
1	Oncogene Proteins (Oncogene Protein)IBA 01/2018
1	AutoantibodiesIBA 01/2018
1	AutoantigensIBA 01/2018
1	serglycinIBA 03/2017
1	MicroRNAs (MicroRNA)IBA 01/2016
1	CalreticulinIBA 01/2015
1	Janus Kinase 2IBA 01/2015
1	Tacrolimus (Prograf)FDA LinkGeneric 08/2010
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 08/2010
1	Calcineurin InhibitorsIBA 08/2010
1	Tumor Biomarkers (Tumor Markers)IBA 07/2010
1	Tuberculin (PPD)IBA 08/2009
1	tributyl phosphate (TBP)IBA 01/2009

Therapy/Procedure

6	Therapeutics 01/2019 - 01/2009
1	Reoperation 09/2023
1	Immunotherapy 01/2022
1	Complementary Therapies (Alternative Medicine) 08/2021
1	Drug Therapy (Chemotherapy) 08/2021
1	Vascular Surgical Procedures 04/2013